Pentafluorosulfanyl serotonin analogs: Synthesis, characterization, and biological activity

ACS Symposium Series

Volumn 1003, Issue , 2009, Pages 165-181

  Welch, John T ^a   Lim, Dongsung ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FUNCTIONALIZATIONS; TRYPTAMINES;

BIOACTIVITY;

EID: 84865732051     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2009-1003.ch008     Document Type: Conference Paper

References (70)

1. Kroeze, W. K.; Roth, B. L., Biological Psychiatry 1998, 44, 1128-1142.
2. Rothman, R. B.; Baumann, M. H., Pharmacology & Therapeutics 2002, 95, 73-88.
3. Rothman, R. B.; Baumann, M. H., Pharmacology, Biochemistry and Behavior 2002, 71, 825-836.
4. Wishart, G.; Bremner, D. H.; Sturrock, K. R., Receptors and Channels 1999, 6, 317-335.
5. Chilmonczyk, Z., J. Pharmacy and Pharmacology 1995, 47, 791-801.
6. Peroutka, S. J., J. Neurochemistry 1993, 60, 408-416.
7. Leff, P.; Martin, G. R., Med. Res. Re. 1988, 8, 187-202.
8. Gillman, P. K., Fundamental & Clinical Pharmacology 1998, 12, 482-491.
9. Carrasco, J. L.; Sandner, C., International J. Clinical Practice 2005, 59, 1428-1434.
10. Hemeryck, A.; Belpaire, F. M., Curr. Drug Metabolism 2002, 3, 13-37.
11. Walsh, M. T.; Dinan, T. G., Acta Psychiatrica Scandinavica 2001, 104, 84-91.
12. Hiemke, C.; Hartter, S., Pharmacology & Therapeutics 1999, 85, (1), 11-28.
13. Halford, J. C. G.; Harrold, J. A.; Lawton, C. L.; Blundell, J. E., Curr. Drug Targets 2005, 6, 201-213.
14. Blundell, J. E.; Halford, J. C. G., CNS Drugs 1998, 9, 473-495.
15. Miller, K. J., Molecular Interventions 2005, 5, 282-291.
16. Eddahibi, S.; Adnot, S., Respiratory Research [online computer file] 2002, 3.
17. McCann, U. D.; Seiden, L. S.; Rubin, L. J.; Ricaurte, G. A., J. Am. Med. Assoc. 1997, 278, 666-672.
18. Kaumann, A. J.; Levy, F. O., Pharmacol. & Therapeutics 2006, 111, 674-706.
19. Ramage, A. G., Brain Res. Bull. 2001, 56, 425-439.
20. Riad, M.; Tong, X. K.; El Mestikawy, S.; Hamon, M.; Hamel, E.; Descarries, L., Neuroscience (Oxfor 86, 1031-1035.
21. Taniyama, K.; Makimoto, N.; Furuichi, A.; Sakurai-Yamashita, Y.; Nagase, Y.; Kaibara, M.; Kanematsu, T., J. Gastroenterology 2000, 35, 575-582.
22. Anthony, M., Australian and New Zealand J. Med. 1984, 14, 888-895.
23. Lentz, D.; Seppelt, K.; Akiba, K. Y., The SF5, SeF5 and TeF5 Groups in Organic Chemistry In Chemistry of Hypervalent Compounds, Akiba, K.-Y., Ed. Wiley-VCH: New York, 1999; pp 295-323.
24. Brant, P.; Berry, A. D.; DeMarco, R. A.; Carter, F. L.; Fox, W. B.; Hashmall, J. A., J. Electron Spectrosc. Relat. Phenom. 1981, 22, 119-129.
25. True, J. E.; Thomas, D.; Winter, R. W.; Gard, G. L., Inorg. Chem. 2003, 42, 4437-4441.
26. Saethre, L. J.; Berrah, N.; Bozek, J. D.; Boerve, K. J.; Carroll, T. X.; Kukk, E.; Gard, G. L.; Winter, R.; Thomas, T. D., J. Am. Chem. Soc. 2001, 123, 10729-10737.
27. Sheppard, W. A., J. Am. Chem. Soc. 1962, 84, 3072-3076.
28. Taft, R. W., Jr., J. Phys. Chem. 1960, 64, 1805-1815.
29. Taft, R. W., Jr.; Lewis, I. C., J. Am. Chem. Soc. 1959, 81, 5343-5352.
30. Winter, R. W.; Dodean, R. A.; Gard, G. L.; Soloshonok, V. A., SF5 Synthons: Pathways to Organic Derivatives of SF6 In Fluorine Containing Synthons, Soloshonok, V. A., Ed. American Chemical Society: Washington D.C., 2005; pp 87-118.
31. Kirsch, P., Modern Fluoroorganic Chemistry. Synthesis, Reactivity and Applications. Wiley-VCH: Weinheim, 2004.
32. Chambers, R. D.; Greenhall, M. P.; Hutchinson, J.; Moilliet, J. S.; Thomson, J., Proceeding of the 211th National Meeting of American Chemical Society, New Orleans, LA 1996, Fluo11.
33. Sipyagin, A. M.; Enshov, V. S.; Kashtanov, S. A.; Bateman, C. P.; Mullen, B. D.; Tan, Y.-T.; Thrasher, J. S., J. Fluor. Chem. 2004, 125, 1305-1316.
34. Kirsch, P.; Bremer, M., Angew. Chem. Inter. Ed. Engl. 2000, 39, 4216-4235.
35. Kirsch, P.; Bremer, M.; Heckmeier, M.; Tarumi, K., Angew. Chem. Inter. Ed. Engl. 1999, 38, 1989-1992.
36. Kirsch, P.; Bremer, M.; Heckmeier, M.; Tarumi, K., Mol.Cryst.Liq.Cryst. 2000, 346, 29-33.
37. Kirsch, P.; Bremer, M.; Taugerbeck, A.; Wallmichrath, T., Angew. Chem. Inter. Ed. Engl 2001, 40, 1480-1484.
38. Soloshonok, V. A.; Mikami, K.; Yamazaki, T.; Welch, J. T.; Honek, J. F., Current Fluoroorganic Chemistry: New Synthetic Directions, Technologies, Materials, and Biological Applications. American Chemical Society: Washington, D.C., 2007.
39. Kirsch, P.; Hahn, A., Eur. J. Org. Chem. 2006, 1125-1131.
40. Kirsch, P.; Hahn, A., Eur. J. Org. Chem. 2005, 3095-3100.
41. Crowley, P. J.; Mitchell, G.; Salmon, R.; Worthington, P. A., Chimia 2004, 58, 138-142.
42. Bossenmaier, B.; Friebe, W. G.; Rueth, M.; Voss, E. 2007. US 7,235,574.
43. Aminul, I.; Chandan, B.; Sahadev, K. Preparation of optically pure zolmitriptan. 2005245585, 2005/04/21/, 2005.
44. Pete, B.; Bitter, I.; Harsanyi, K.; Toke, L., Heterocycles 2000, 53, 665-673.
45. Hagen, T. J.; Narayanan, K.; Names, J.; Cook, J. M., J. Org. Chem. 1989, 54, 2170-2178.
46. Narayanan, K.; Cook, J. M., J. Org. Chem. 1991, 56, 5733-5736.
47. Wong, D. T.; Perry, K. W.; Bymaster, F. P., Nature Reviews Drug Discovery 2005, 4, 764-774.
48. Wong, D. T.; Horng, J. S.; Bymaster, F. P.; Hauser, K. L.; Molloy, B. B., Life Sciences 1974, 471-479.
49. Stokes, P. E.; Holtz, A., Clinical Therapeutics 1997, 19, 1135-1250.
50. Wong, D. T.; Bymaster, F. P.; Engleman, E. A., Life Sciences 1995, 57, 411-441.
51. Hurst, M.; Lamb, H. M., CNS Drugs 2000, 14, 51-80.
52. Simpson, K.; Noble, S., CNS Drugs 2000, 14, 301-328.
53. Cheer, S. M.; Goa, K. L., Drugs 2001, 61, 81-110.
54. Welch, J. T.; Lim, D. S., Bioorg. Med. Chem. 2007, 15, 6659-6666.
55. Concepcion, P. T. Process for the preparation of N-methyl-3-phenyl-3-(p- trifluoromethylphenoxy) propylamine. 1997.
56. Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.; Hufeisen, S. J.; Roth, B. L., Circulation 2000, 102, 2836-2841.
57. Schiller, N. B., J. Am. Coll. Cardiology 1999, 34, 1159-1162.
58. Rogers, P. J.; Blundell, J. E., Psychopharmacology (Berlin, Germany) 1979, 66, 159-165.
59. Guy-Grand, B., Am. J. Clinical Nutrition 1992, 55, (1 Suppl), 173S-176S.
60. Davis, R.; Faulds, D., Drugs 1996, 52, 696-724.
61. Simansky, K. J., Behavioural Brain Research 1996, 73, 37-42.
62. Vivero, L. E.; Anderson, P. O.; Clark, R. F., J. Emergency Med. 1998, 16, 197-205.
63. Weintraub, M.; Sundaresan, P. R.; Madan, M.; Schuster, B.; Balder, A.; Lasagna, L.; Cox, C., Clinical Pharmacology and Therapeutics 1992, 51, 586-594.
64. Connolly, H. M.; Crary, J. L.; McGoon, M.; Hensrud, D. D.; Edwards, D. S.; Edwards, W. D.; Schaff, H. V., New Eng. J. Med. 1997, 337, 581-588.
65. Rothman, R. B.; Baumann, M. H., Drug Development Research 2000, 51, 52-65.
66. Curzon, G.; Gibson, E. L.; Oluyomi, A. O., Trends in Pharmacological Sciences 1997, 18, 21-25.
67. Fitzgerald, L. W.; Burn, T. C.; Brown, B. S.; Patterson, J. P.; Corjay, M. H.; Valentine, P. A.; Sun, J.-H.; Link, J. R.; Abbaszade, I.; Hollis, J. M.; Largent, B. L.; Hartig, P. R.; Hollis, G. F.; Meunier, P. C.; Robichaud, A. J.; Robertson, D. W., Molecular Pharmacology 2000, 57, 75-81.
68. Roth, B. L., New Eng. J. Med. 2007, 356, 6-9.
69. Duan, J.; Zhang, L. H.; Dolbier, W. R., Synlett 1999, 1245-1246.
70. Branchek, T. A.; Blackburn, T. P., Ann. Rev. Pharmacology and Toxicology 2000, 40, 319-334.